Sign Up For Our Newsletter
Sign Up For Our Newsletter
PYC is using its expertise in RNA drug design and proprietary drug delivery technology to bring a powerful new class of precision medicine to patients. With an initial focus on rare eye disease, PYC’s technology has the potential to unlock treatments for multiple types of genetic disease.

PYC Therapeutics Delivering the Potential of Precision Medicine

PYC is using its expertise in RNA drug design and proprietary drug delivery technology to bring a powerful new class of precision medicine to patients. With an initial focus on rare eye disease, PYC’s technology has the potential to unlock treatments for multiple types of genetic disease.
  • The company has proven the efficacy and safety of its lead drug program in patient-derived models and has launched formal studies in preparation for human clinical trials in 2021.
  • PYC is advancing several earlier stage retinal assets and is applying its technology in other tissues including CNS and liver.
  • With its research operations based in Australia, PYC recently opened its office in Cambridge, Massachusetts, where the CEO and Chief Medical Officer are now based.
In the short-term, PYC will further de-risk its lead program through pre-clinical toxicity studies, obtain Orphan Drug Designation from the FDA, and file provisional patents for additional drug programs. In the long-term, PYC is building a global RNA therapeutics company with multiple drugs providing treatment to patients with a variety of genetic diseases.
 
PYC is an emerging company with differentiated technology operating in a field with tremendous growth. The company’s lead asset has been significantly de-risked, and PYC’s broader drug pipeline and technology hold the potential for massive growth.